TRCT
ADIL

Tower Research Capital (TRC)’s Adial Pharmaceuticals ADIL Stock Holding History

Tower Research Capital (TRC)’s Portfolio ADIL Stock Details ADIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.43K Buy
1,356
+1,302
+2,411% +$4.58K ﹤0.01% 4481
2025
Q4 		$295 Sell
54
-1
-2% -$8 ﹤0.01% 4949
2025
Q3 		$484 Sell
55
-2
-4% -$19 ﹤0.01% 5002
2025
Q2 		$429 Hold
57
– – ﹤0.01% 5027
2025
Q1 		$905 Buy
57
+31
+119% +$640 ﹤0.01% 4806
2024
Q4 		$644 Sell
26
-132
-84% -$3.44K ﹤0.01% 5214
2024
Q3 		$3.94K Sell
158
-67
-30% -$1.75K ﹤0.01% 4732
2024
Q2 		$6.48K Buy
225
+40
+22% +$1.51K ﹤0.01% 4575
2024
Q1 		$6.15K Buy
185
+16
+9% +$599 ﹤0.01% 4425
2023
Q4 		$7.88K Buy
+169
New +$9.26K ﹤0.01% 4569
2022
Q3 		– Sell
-11
Closed -$9K – 6016
2022
Q2 		$9K Buy
11
+3
+38% +$2.72K ﹤0.01% 4533
2022
Q1 		$11K Buy
+8
New +$11K ﹤0.01% 4137
2021
Q4 		– Hold
0
– – – 6094
2021
Q3 		– Sell
-1
Closed -$2.09K – 5722
2021
Q2 		$1K Sell
1
-1
-50% -$1.52K ﹤0.01% 5162
2021
Q1 		$3K Sell
2
-1
-33% -$1.51K ﹤0.01% 4874
2020
Q4 		$3K Sell
3
-1
-25% -$1.18K ﹤0.01% 4774
2020
Q3 		$5K Buy
+4
New +$3.73K ﹤0.01% 4336
2018
Q4 		– Sell
-1
Closed -$2K – 3779
2018
Q3 		$2K Buy
+1
New +$2.08K ﹤0.01% 3395

Other funds holding ADIL

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
MCM
Manchester Capital Management Manchester, Vermont $694M AUM 22.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Tower Research Capital (TRC)'s ADIL Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Adial Pharmaceuticals (ADIL) stake by 2,411% in Q1 2026, buying an estimated $4.58K and bringing the position to 1,356 shares worth $2.43K. The position accounts for ﹤0.01% of the portfolio, ranked #4481.

Tower Research Capital (TRC) first reported a position in ADIL in Q3 2018 and has held it in 17 quarters since. The position peaked at $11K in Q1 2022. 14 funds tracked by Wall St. Rank hold ADIL as of Q1 2026.

  • Tower Research Capital (TRC) held 1,356 shares of Adial Pharmaceuticals worth $2.43K as of Q1 2026.
  • Tower Research Capital (TRC) bought 1,302 Adial Pharmaceuticals shares in Q1 2026, an estimated $4.58K.
  • Adial Pharmaceuticals made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #4481 holding.
  • Tower Research Capital (TRC) first reported a position in Adial Pharmaceuticals in Q3 2018 and has held it in 17 quarters since.
  • Tower Research Capital (TRC)'s Adial Pharmaceuticals position peaked at $11K in Q1 2022.
  • 14 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.